SPARC binding ScFcs

Patent metadata

Field	Value
Publication number	US-9295733-B2
Application number	US-201414448696-A
Country	US
Kind code	B2
Filing date	Jul 31, 2014
Priority date	Dec 5, 2008
Publication date	Mar 29, 2016
Grant date	Mar 29, 2016

Abstract

The invention provides compositions comprising SPARC binding ScFc and its use.

First claim

The invention claimed is:

1. A composition comprising an ScFv which binds to a SPARC protein, wherein the ScFv consists of the sequence of SEQ ID NO: 113.

2. The composition of claim 1 , wherein the ScFv is coupled to a therapeutic agent or diagnostic agent.

3. The composition of claim 2 wherein the therapeutic agent is an antibody fragment comprising a functional antibody Fc domain.

4. The composition of claim 3 , wherein the functional antibody Fc domain comprises SEQ ID NO: 118.

5. The composition of claim 2 , wherein the therapeutic agent is selected from the group consisting of radionuclides, adriamycin, ansamycin antibiotics, asparaginase, bleomycin, busulphan, cisplatin, carboplatin, cannustine, capecitabine, chlorambucil, cytarabine, cyclophosphamide, camptothecin, dacarbazine, dactinomycin, daunorubicin, dexrazoxane, docetaxel, doxorubicin, etoposide, epothilones, floxuridine, fludarabine, fluorouracil, gemcitabine, hydroxyurea, idarubicin, ifosfamide, irinotecan, lomustine, mechlorethamine, mercaptopurine, meplhalan, methotrexate, rapamycin (sirolimus), mitomycin, mitotane, mitoxantrone, nitrosurea, paclitaxel, pamidronate, pentostatin, plicamycin, procarbazine, rituximab, streptozocin, teniposide, thioguanine, thiotepa, taxanes, vinblastine, vincristine, vinorelbine, TAXOL, combretastatins, discodermolides, transplatinmn, docetaxel, paclitaxel, taxanes, 5-fluorouracil, genistein, tTF, TNF, Smarl derived p44 peptide, interferon, TRAIL, Smac, VHL, procaspase, caspase, and IL-2, a non-Fe domain antibody fragment, and combinations thereof.

6. The composition of claim 2 , wherein the therapeutic or diagnostic agent is a diagnostic agent selected from the group consisting of radioactive agents, MRI contrast agents, X-ray contrast agents, ultrasound contrast agents, and PET contrast agents.

7. The composition of claim 1 , further comprising a pharmaceutical carrier.

Assignees

• Abraxis Bioscience Llc

Inventors

• Trieu Vuong

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title